Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1192 studies found for:    BCR
Show Display Options
Rank Status Study
1 Recruiting Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
Conditions: Philadelphia Positive;   BCR-ABL Positive;   Acute Lymphoblastic Leukemia
Intervention: Drug: Ponatinib
2 Recruiting Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
Conditions: Chronic Myeloid Leukemia;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: PF-114
3 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
Intervention:
4 Terminated Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL
Condition: Acute Lymphoblastic Leukemia
Intervention:
5 Completed Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase
Condition: Leukemia, Myeloid
Intervention: Drug: Nilotinib
6 Active, not recruiting Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
Conditions: Leukemia;   Leukemia, Myeloid;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Philadelphia Chromosome;   Hematologic Diseases
Intervention: Drug: Radotinib
7 Active, not recruiting Nilotinib in PH+, BCR-, ABL+ CML Patients
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
8 Recruiting Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML
Conditions: Chronic Myeloid Leukemia in Myeloid Blast Crisis;   Untreated Adult Acute Myeloid Leukemia
Intervention: Drug: Nilotinib+AD induction
9 Recruiting Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years
Condition: Acute Lymphoblastic Leukemia Ph Positive
Interventions: Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine
10 Completed Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: imatinib;   Drug: cyclophosphamide;   Drug: daunorubicin;   Drug: vincristine;   Drug: prednisolone;   Drug: methotrexate;   Drug: cytarabine;   Drug: dexamethasone
11 Completed Safety Assessment of a Multipeptide-gene Vaccine in CML
Condition: Leukemia, Myeloid, Chronic
Interventions: Biological: Bcr-abl multipeptide vaccine;   Genetic: Cytokine gene adjuvant
12 Active, not recruiting Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL
Conditions: Acute Lymphoblastic Leukemia;   Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Ara-C
13 Recruiting Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Condition: Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
14 Unknown  TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia;   Stem Cell Transplantation;   Minimal Residual Disease
Intervention: Drug: TKI
15 Completed
Has Results
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Omacetaxine mepesuccinate
16 Not yet recruiting ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Condition: Recurrent Chronic Lymphoid Leukemia
Interventions: Drug: ACY-1215;   Drug: Ibrutinib;   Drug: Idelalisib
17 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
18 Recruiting Transvaginal Treatment of Symptomatic Cystocele Grade II-III
Condition: Cystocele
Intervention: Device: cystocele repair with biomesh soft prolaps and endofast reliant
19 Terminated
Has Results
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Condition: Leukemia
Interventions: Biological: bcr-abl peptide vaccine;   Genetic: reverse transcriptase-polymerase chain reaction
20 Completed A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Conditions: Myelofibrosis;   Myeloid Metaplasia;   Agnogenic Myeloid Metaplasia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Imatinib mesylate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years